SNCA and Parkinson disease: We highlight for the first time that genetic knockdown of p32 and pharmacological p32 inhibition can ameliorate disease phenotypes in hCHCHD2-linked PD models likely through improvement of mitochondria morphology/function and reduction of α-synuclein level.